BHCM
ZBIO icon

Brevan Howard Capital Management’s Zenas BioPharma ZBIO Stock Holding History

Brevan Howard Capital Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$372K Buy
+14,674
New +$292K ﹤0.01% 1586
2026
Q1 		– Sell
-6,173
Closed -$224K – 2572
2025
Q4 		$224K Buy
+6,173
New +$203K ﹤0.01% 1523

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Brevan Howard Capital Management's ZBIO Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Zenas BioPharma (ZBIO) in Q2 2026: 14,674 shares worth $372K. The stake represents ﹤0.01% of the portfolio and ranks #1586 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in ZBIO as recently as Q4 2025.

Brevan Howard Capital Management first reported a position in ZBIO in Q4 2025 and has held it in 2 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Brevan Howard Capital Management held 14,674 shares of Zenas BioPharma worth $372K as of Q2 2026.
  • Zenas BioPharma was a new Brevan Howard Capital Management position in Q2 2026.
  • Zenas BioPharma made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1586 holding.
  • Brevan Howard Capital Management first reported a position in Zenas BioPharma in Q4 2025 and has held it in 2 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.